7月9日，Definium Therapeutics盘中上涨5.09%，报47.625美元/股，成交额6690.95万美元。
消息面上，公司此前公布其核心产品DT120口崩片治疗重度抑郁症的3期EMERGE研究取得积极顶线结果，达到主要终点及所有关键次要疗效终点，安全性特征良好。随后公司迅速启动融资，完成规模达8.05亿美元的增发（承销商全额行使超额配售权），发行价34美元/股，募资将用于DT120研发及潜在商业化准备。RBC Capital随之将目标价由36美元大幅上调至57美元，维持"跑赢大市"评级。关键临床数据验证叠加充裕资金保障，持续推动股价上行。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.